New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 24, 2013
10:00 EDTVOCS, SBRA, DV, AAPL, UGI, FCX, CREE, VTR, IRWD, EW, T, O, MHR, TSS, THRX, DFS, AMGN, NNN, GAS, GSSOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AT&T (T) downgraded to Equal Weight from Overweight at Morgan Stanley... Amgen (AMGN) downgraded to Neutral from Overweight at Piper Jaffray... Apple (AAPL) downgraded to Market Perform from Outperform at BMO Capital... DeVry (DV) downgraded to Hold from Buy at Deutsche Bank... Dice Holdings (DHX) downgraded to Market Perform from Outperform at William BlairDiscover (DFS) downgraded to Hold from Buy at Jefferies... Edwards Lifesciences (EW) downgraded to Neutral from Buy at Lazard Capital... Ironwood (IRWD) downgraded to Equal Weight from Overweight at Morgan Stanley... Sabra Health Care (SBRA) downgraded to Hold from Buy at Jefferies... Theravance (THRX) downgraded to Market Perform from Outperform at Bernstein... Total System (TSS) downgraded to Hold from Buy at Deutsche Bank... Ventas (VTR) downgraded to Hold from Buy at Jefferies... Vocus (VOCS) downgraded to Market Perform from Outperform at Barrington... Cree (CREE) downgraded to Hold from Buy at Gabelli... Magnum Hunter (MHR) downgraded to Neutral from Add at Capital One... Golden Star Resources (GSS) downgraded to Underperform from Sector Perform at Scotia... Vocus (VOCS) downgraded to Hold from Buy at Stifel... Freeport McMoRan (FCX) downgraded to Hold from Buy at Argus... Ironwood (IRWD) downgraded to Underperform from Neutral at Wedbush... UGI Corporation (UGI) downgraded to Market Perform from Outperform at BMO Capital... AGL Resources (GAS) downgraded to Underperform from Market Perform at BMO Capital... Realty Income (O) downgraded to Neutral from Outperform at RW Baird... National Retail Properties (NNN) downgraded to Neutral from Outperform at RW Baird... Dice Holdings (DHX) downgraded to Market Perform from Outperform at BMO Capital.
News For T;AAPL;AMGN;EW;DV;DFS;IRWD;SBRA;THRX;VTR;VOCS;TSS;CREE;GSS;MHR;FCX;GAS;O;UGI;NNN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
December 8, 2014
06:15 EDTAAPLLenovo shipments expected to lead Samsung by 9M in 2015, DigiTimes reports
Lenovo (LNVGY) is estimated to beat Samsung (SSNLF) in mobile device shipments in 2015 by about 9M units, reports DigiTimes Research. Lenovo is set to beat Samsung by about 1M units in 2014 and become the second largest mobile computing device brand vendor worldwide behind Apple (AAPL). DigiTimes Research says Lenovo and Samsung plan to focus on maintaining tablet shipments as demand weakens in 2015. Reference Link
06:05 EDTEWEdwards Lifesciences to host investor meeting
Subscribe for More Information
05:55 EDTSBRASabra Health Care downgraded to Hold from Buy at Jefferies
Jefferies downgraded Sabra Health Care REIT to Hold with a $30 price target citing valuation.
05:42 EDTAMGNSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
December 7, 2014
14:38 EDTAMGNAmgen announces new data from Phase 2 BLINCYTO immunotherapy study
Amgen announced new data from the Phase 2 BLAST study which evaluated the bispecific T cell engager, BiTE, immunotherapy BLINCYTO in patients with minimal residual disease, MRD, positive B-cell precursor acute lymphoblastic leukemia, ALL. In the study, 78% of patients who received BLINCYTO experienced a complete MRD response , a measure of eradication of residual disease at the molecular level, after one treatment cycle. Nearly all complete responses occurred within the first treatment cycle. The results from the BLAST study will be featured during the 56th American Society of Hematology Annual Meeting and Exposition press briefing on Saturday, December 6, at 10 a.m. PT and will be presented in an oral session at ASH on Monday, December 8, at 10:30 a.m. PT. "BLINCYTO is the most advanced of Amgen's BiTE immunotherapies, a new and innovative approach that helps the body's own immune system fight cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Achieving molecular complete remission is an important goal in the treatment of ALL, and the data presented at ASH demonstrates that BLINCYTO can produce deep responses in patients that have trace amounts of residual disease." MRD is a state of disease in which the microscopic analysis does not show malignant cells, but more sensitive techniques still detect disease at the molecular level. Patients who have persistent or recurrent MRD after their first therapy have a higher risk of relapse than those with no detectable MRD. In addition to the majority of patients achieving a compete MRD response within one cycle of treatment, 80% achieved a complete MRD response across all cycles. Responses occurred in all subgroups including older patients and patients with high MRD level; no predictive factor for MRD response was identified. In the study, adverse events of all grades occurring in 20% or more patients included pyrexia, tremor, chills, fatigue, nausea, vomiting and diarrhea. Grade =3 AEs occurring in five percent or more patients included neutropenia , pyrexia and tremor. Two fatal AEs occurred on treatment: subdural hemorrhage and pneumonitis in conjunction with influenza. Treatment interruptions due to AEs occurred in 31% of patients.
14:18 EDTAMGNAmgen, Onyx announce detailed results from Phase 3 ASPIRE study of Kyprolis
Subscribe for More Information
14:10 EDTAMGNAmerican Society of Hematology to hold a meeting
Subscribe for More Information
December 5, 2014
17:04 EDTVTRVentas files to sell 148,241 shares of common stock for holders
Subscribe for More Information
11:23 EDTAAPLOption volume leaders
Subscribe for More Information
10:25 EDTNNNNational Retail Properties management to meet with FBR Capital
Meeting to be held in the Mid-Atlantic area on December 9 hosted by FBR Capital.
10:00 EDTEWOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Acorda Therapeutics (ACOR) initiated with a Neutral at Goldman... Builders FirstSource (BLDR) initiated with a Neutral at Sterne Agee... CSI Compressco (CCLP) initiated with a Buy at Stifel... California Resources Corp. (CRC) initiated with a Market Perform at Raymond James... Castlight Health (CSLT) initiated with an Equal Weight at First Analysis... DCP Midstream (DPM) initiated with a Buy at MLV & Co.... DSP Group (DSPG) initiated with an Outperform at Imperial Capital... Edwards Lifesciences (EW) initiated with an Outperform at Bernstein... EnLink Midstream (ENLK) initiated with a Buy at MLV & Co.... Facebook (FB) initiated with a Buy at MKM Partners... FireEye (FEYE) initiated with a Market Perform at JMP Securities... FleetCor (FLT) initiated with a Buy at Deutsche Bank... Imperva (IMPV) initiated with a Buy at Nomura... Keryx (KERX) initiated with an Outperform at Cowen... Knowles (KN) initiated with a Market Perform at FBR Capital... Marlin Midstream (FISH) initiated with a Buy at MLV & Co.... Paragon Offshore (PGN) initiated with a Sector Perform at Iberia... PepsiCo (PEP) initiated with a Buy at Evercore ISI... Proofpoint (PFPT) initiated with a Buy at Nomura... Relypsa (RLYP) initiated with an Outperform at Oppenheimer... Rocket Fuel (FUEL) initiated with a Sell at Maxim... Sprouts Farmers Markets (SFM) initiated with an Underperform at Longbow... Summit Midstream (SMLP) initiated with a Buy at MLV & Co.... TubeMogul (TUBE) initiated with a Buy at Maxim... Western Gas Partners (WES) initiated with a Buy at MLV & Co.
10:00 EDTNNNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:36 EDTAAPLActive equity options trading
Subscribe for More Information
08:15 EDTNNNNational Retail Properties upgraded at BofA/Merrill
Subscribe for More Information
07:45 EDTAAPLConsensus on Apple iPhone units could be low, says UBS
Subscribe for More Information
07:13 EDTEWEdwards Lifesciences initiated with an Outperform at Bernstein
Subscribe for More Information
06:41 EDTAAPLApple questions validity of plaintiffs in iPod case, NY Times says
Subscribe for More Information
06:06 EDTNNNNational Retail Properties upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
06:03 EDTAAPLiOS mobile traffic shows iPhone 6 launch strong, says Piper Jaffray
Piper Jaffray says that according to Quantcast data, Apple's (AAPL) iOS mobile traffic share increased from 60.6% at iPhone 6 launch to 61.4% nine weeks after launch, while Google's (GOOG) Android decreased from 38.4% to 37.5% in the same period. Piper views the iOS mobile traffic share as further evidence that the iPhone 6 launch in the U.S. is off to a strong start. It keeps an Overweight rating on Apple shares with a $135 price target.
06:01 EDTTTechNet: Combined AT&T/DirecTV will increase broadband development
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use